Several seminal studies have shown that mutant recombinant seeds or human brain-derived tau seeds obtained from neurodegenerative diseases with unique clinical presentations have different seeding and aggregation properties in vitro and in vivo [24, 29–33]. The gene discussed is MAPT; the disease is neurodegenerative disease.